Nuvectis Pharma (NASDAQ:NVCT) Trading Up 6.6% – Should You Buy?

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) traded up 6.6% during trading on Friday . The stock traded as high as $23.87 and last traded at $23.9650. Approximately 97,131 shares traded hands during mid-day trading, a decline of 42% from the average daily volume of 168,102 shares. The stock had previously closed at $22.49.

Analyst Ratings Changes

NVCT has been the topic of a number of research reports. HC Wainwright lifted their price target on shares of Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Loop Capital set a $40.00 target price on Nuvectis Pharma in a report on Tuesday, September 1st. Weiss Ratings downgraded Nuvectis Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 4th. Roth Capital increased their price target on Nuvectis Pharma from $20.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, July 6th. Finally, Lucid Cap Mkts upgraded Nuvectis Pharma to a “strong-buy” rating in a report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.25.

Nuvectis Pharma Stock Performance

The stock has a market cap of $777.65 million, a P/E ratio of -18.33 and a beta of -0.26. The stock’s fifty day moving average is $20.99 and its 200 day moving average is $14.29.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Equities research analysts predict that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Insider Buying and Selling

In related news, CEO Ron Bentsur bought 12,500 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were purchased at an average price of $20.00 per share, with a total value of $250,000.00. Following the transaction, the chief executive officer owned 3,688,424 shares in the company, valued at $73,768,480. This trade represents a 0.34% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Marlio Charles Mosseri purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were bought at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the acquisition, the insider directly owned 3,186,576 shares in the company, valued at $58,378,072.32. This trade represents a 1.59% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 28.55% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nuvectis Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System lifted its holdings in shares of Nuvectis Pharma by 376.8% in the 2nd quarter. California State Teachers Retirement System now owns 3,991 shares of the company’s stock worth $73,000 after acquiring an additional 3,154 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in Nuvectis Pharma during the 2nd quarter valued at about $5,057,000. Stonepine Capital Management LLC bought a new position in Nuvectis Pharma during the 2nd quarter valued at about $735,600. Bank of America Corp DE purchased a new stake in Nuvectis Pharma in the 2nd quarter worth about $218,000. Finally, Legal & General Group Plc purchased a new stake in Nuvectis Pharma in the 2nd quarter worth about $31,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.